1. [Coagulopathy and COVID-19. Recommendations for a changing reality].
- Author
-
Riveros D, Maymó D, Laviano J, Fornillo FF, Fernández J, Benzadon R, Solimano J, Cacchione R, Riera L, Duarte P, Cazap N, Gotta D, García Altuve J, Valentini R, and Dupont J
- Subjects
- Argentina epidemiology, Betacoronavirus, Blood Coagulation Disorders diagnosis, Blood Coagulation Disorders epidemiology, Blood Coagulation Disorders prevention & control, COVID-19, Coronavirus Infections complications, Coronavirus Infections epidemiology, Cytokines, Disseminated Intravascular Coagulation, Heparin, Humans, Pneumonia, Viral complications, Pneumonia, Viral epidemiology, SARS-CoV-2, Sepsis, Blood Coagulation Disorders etiology, Coronavirus, Coronavirus Infections blood, Pandemics, Pneumonia, Viral blood, Thromboembolism complications
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic requires rapid medical responses. The risk of venous and arterial thromboembolism increases in critically ill patients with SARS-CoV-2 infection. There is a hypercoagulable state that includes elevated levels of D-dimer, with an increased risk of organ failure and increased mortality. The abnormalities described in hemostasis should be considered for therapeutic decision making. We analyzed the available scientific evidence for the therapeutic approach of coagulopathy in the course of the disease with the objective of designing realistic therapeutic recommendations aimed at reducing morbidity and mortality in patients with COVID-19.
- Published
- 2020